Peri- or postmenopausal women suffering from vulvovaginal atrophy (VVA)
Breast cancer survivors with VVA symptoms
Understand the study, be willing to participate, and sign an informed consent form.
The use of estrogen/progestogen-based products (vaginal, oral, pellets, transdermal, etc.) is permitted but must be documented (this will be considered during randomization).
You may not be if
Undiagnosed abnormal genital bleeding.
Administration of any investigational drug within 30 days prior to the screening visit.
Presence of a serious medical condition, neurological disorder, or significant comorbidities.
Other gynecological malignancies.
Recent vaginal surgery.
Clinically significant prolapse (POP-Q ≤ 2).
Current urinary tract or vaginal infection, or recent sexually transmitted infection.
Individuals with disabilities unable to communicate.
Women eligible for the study but unwilling to participate.
Clareo Health | Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
